NCT02436096Phase 3Completed

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

Study sponsor: Tonix Pharmaceuticals, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2016-09Actual
Enrollment · participants519Actual
Source updated2025-02-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview